The measurement of precursor frequencies of donor anti-recipient cytotoxic T lymphocytes (CTL-p) has been shown to predict the incidence and the severity of acute graft-versus-host disease (aGVHD) in unrelated donor bone marrow transplantation (BMT). In HLAidentical sibling BMT, where aGVHD is most likely caused by minor histocompatibility antigen mismatches, this assay did not appear to be sensitive enough to provide similar predictive information. In this study, the CTL-p frequencies and the incidence and severity of aGVHD in 51 onco-hematological patients transplanted from HLA-identical siblings were compared. Sibling donors were selected on the basis of HLA identity using serological typing for HLA-A, B, C antigens, whereas HLA-DRB was tested by molecular analysis. Sibling identity was also confirmed by DNA heteroduplex analyses. 
Current matching policies are based on the achievement of a 'structural matching', ie donor-recipient identity for the HLA antigens or genes analyzed. 3 Nevertheless, there is no clear evidence that structural matching for HLA alleles gives an absolute guarantee for successful transplantation: acute GVHD (aGVHD) may occur even when the donor is a genetically HLA-identical sibling of the patient, whereas some recipients of donor marrow with known HLA mismatches do not develop aGVHD. 4 In this context, the definition of 'functional matching' may be relevant in order to assess the clinical importance of mismatches for known HLA antigens, minor histocompatibility antigens (mHA) or undefined antigens not detected by current methods. [5] [6] [7] [8] Functional assays, by measuring in vitro alloreactivity, mimic graft-versus-host reactions and help to predict whether structural mismatches will be accepted by the immune system of the donor. Formerly, the mixed lymphocyte culture (MLC) was the only widely used functional assay, but it proved a poor predictor of aGVHD development. 9, 10 Therefore, several other functional assays were investigated. 11, 12 Limiting dilution analysis is now considered the best available method to monitor the frequency of alloreactive cytotoxic and helper T lymphocytes. The frequencies of donor anti-recipient cytotoxic and helper T lymphocyte precursors (CTL-p and HTL-p) were shown to predict the occurrence of aGVHD after BMT. 5, 7 Although in HLAmatched unrelated donors both assays provide similar predictive information, 13 in HLA-identical siblings it has been observed that CTL-p evaluation has a relatively low sensitivity in detecting the anti-mHA alloreactivity. 7, [14] [15] [16] [17] In the present study, the CTL-p frequency and the incidence and severity of aGVHD in 51 patients transplanted from HLA-identical siblings were compared, to assess whether the presence of alloreactive T cells before transplantation may provide a clinically useful tool to evaluate histocompatibility in HLA-identical sibling BMT.
Patients and methods

Patients
Fifty-one patients, 32 males and 19 females, 18-57 years of age (mean = 38 years), received BMT from HLA-identical sibling donors between February 1996 and October 1999.
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Diagnoses were acute myeloid leukemia (AML) in 16 patients, acute lymphoblastic leukemia (ALL) in 11, chronic myeloid leukemia (CML) in 11, myelodysplastic syndrome (MDS) in seven, non-Hodgkin's lymphoma (NHL) in three, multiple myeloma (MM) in two and Hodgkin's disease (HD) in one. Patient characteristics are presented in Table 1 . AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myeloid leukemia; MDS = myelodysplastic syndrome; NHL = non-Hodgkin's lymphoma; MM = multiple myeloma; HD = Hodgkin's disease; THIO = thiotepa; CY = cyclophosphamide; BU = busulfan; TBI = totalbody irradiation; aGVHD = acute graft-versus-host disease; cGVHD = chronic graft-versus-host disease; ne = not evaluable; MOF = multi-organ failure; TRM = transplant-related mortality; CNS = central nervous system; IP = interstitial pneumonia. 
Conditioning regimen and GVHD prophylaxis
HLA matching
Sibling donors were selected on the basis of HLA identity using serological typing for HLA-A, B, C antigens, whereas HLA-DRB was tested by molecular analysis (PCR-SSO using the XII International Histocompatibility Workshop protocols or PCR-SSP with commercial kits). Sibling identity was also confirmed by DNA heteroduplex analysis for HLA-A, B, C, DR, DQ, DP loci. 18 Where possible, HLA genotypic identity was checked by family studies.
Cell preparation
Heparinized peripheral blood was drawn from healthy volunteers and from donors and patients prior to BMT. Peripheral blood mononuclear cells (PBMC) were separated by centrifugation on Ficoll-Hypaque and used fresh.
Limiting dilution assay
All assays were performed in the GVH direction, with donor cells as responders and recipient cells as stimulators. The culture medium was RPMI 1640 supplemented with 2 mm l-glutamine, 100 IU/ml penicillin, 100 g/ml streptomycin, and 10% fetal calf serum (Hyclone, Celbio, Logan, UT, USA); the serum was screened for its ability to support cell proliferation and cytotoxic responses specific against the original stimulator. Limiting numbers of responder PBMC (5 ϫ 10 4 Ϫ1.5 ϫ 10 3 ) were cultured in 96-well round-bottom microtiter plates with a constant number (5 ϫ 10 4 ) of irradiated (3000 rads) stimulator PBMC. Twentyfour replicates for each responder dilution were set up. As a negative control, irradiated stimulator cells were cultured without responders; a positive control was performed using a third party (an HLA-incompatible individual) as stimulator. An autologous control was also performed. On day 3 a final concentration of 5 U/ml of recombinant human interleukin-2 (rIL-2) was added to the cultures. On day 7 the cultures were assayed for cytolytic activity against 51 Crlabeled OKT3-induced blasts from the original stimulators.
OKT3-induced blasts
Blast transformation was achieved by culturing stimulator PBMC in six-well flat-bottomed plates where OKT3 mAb was immobilized to plastic macrowells. 19, 20 Briefly, OKT3 mAb was diluted in phosphate-buffered saline (PBS) at a final concentration of 0.125 g/ml and 6 ml of this solution was dispensed into the macrowells. After 2 h of incubation at room temperature, wells were washed twice with culture medium. Residual binding sites were saturated by culture medium for 1 h of incubation at room temperature. Stimulator PBMC were cultured at 10 6 /ml in culture medium with 5 U/ml rIL-2 for 7 days at 37°C in a humidiBone Marrow Transplantation fied atmosphere of 5% CO 2 in air. Cultures were split every 2 or 3 days, fresh medium containing rIL-2 being added to the cultures each time.
Cytotoxicity assay
On day 7 the target blast cells were labeled with 51 Cr, 200 Ci/10 7 cells for 1 h, then washed twice and added to the culture plates (1 ϫ 10 4 per well). The plates were incubated for 4 h and centrifuged. Then, 50 l of supernatant was harvested from the assay wells and transferred to 96-well solid scintillator-coated plates (Lumaplate, Packard, Meriden, CT, USA); the amount of 51 Cr release was evaluated by a ␤-counter (Microbeta Trilux, Wallac, Turku, Finland). Spontaneous and total release was also determined.
Calculation of CTL-p frequencies
Wells were scored as positive if 51 Cr release was greater than mean plus 3 s.d. of the negative control. The frequency of responding cells was determined by the chi-square minimization estimation 21 using a computer program, while the variance was estimated by the use of 95% confidence intervals. All data were examined to be in accordance with single-hit kinetics.
Statistical analysis
Correlation of CTL-p frequency with clinical data was assessed using Student's t-test or Mann-Whitney test for continuous data (donor and patient age, aGVHD onset and time to engraftment), and Fisher exact test (2-tail) for categorical data (aGVHD, relapse and sex mismatch). A chisquare test for linear trend was used for assessing differences in aGVHD.
Results
CTL-p frequency and aGVHD
From the clinical point of view, aGVHD was classified according to the Seattle criteria (grades 0-I = not clinically significant; grades II-IV = clinically significant), as described by Glucksberg et al. 22 All patients had sustained engraftment and were evaluable for the presence of aGVHD. Of the 51 patients studied, six died within the first 100 days. Five of them developed aGVHD grades II-IV. Only one patient died after 2 months, without evidence of aGVHD, due to relapse.
CTL-p frequency analysis was performed, prior to BMT, in all 51 patients. A graphic representation of the CTL-p frequencies in patients with grades 0-I aGVHD vs patients with grades II-IV aGVHD is reported in Figure 1 . Donor/recipient pairs were divided into a high (Ͼ1:100 ϫ 10 3 ) CTL-p frequency (HF) group and a low (Ͻ1:100 ϫ 10 3 ) CTL-p frequency (LF) group, as defined by previous studies. [5] [6] [7] 15, 23 Fifteen out of 21 (71%), from the HF group, and 12 out of 30 (40%), from the LF group, had clinically significant aGVHD (Table 2) . Sensitivity, specificity, pos- itive predictive value (PPV) and odds ratio (OR) of a HF vs LF CTL-p for prediction of grades II-IV aGVHD are reported in Table 2 . A significant correlation (P = 0.04) between CTL-p frequency and severity of aGVHD was demonstrated (Table 3) . Moreover there was a positive trend for an HF response according to an increasing grade of aGVHD, which was statistically significant (P = 0.04) ( Table 3) .
CTL-p frequency and other clinical data
A comparison between CTL-p frequency and patient or donor age, time to engraftment, source of stem cells, sex mismatch (i.e. female donor/male recipient), aGVHD onset and relapse was also performed. Statistical analysis revealed a shorter platelet engraftment time in patients with high CTL-p frequency (P = 0.018) ( Table 3) . No significant differences were detected in the HF and LF groups with respect to other clinical parameters (Table 3) .
Discussion
Minor histocompatibility antigen (mHA) mismatches between patient and donor are the main factors responsible for alloreactivity causing aGVHD and graft-versus-leukemia (GVL) reaction in HLA-identical sibling BMT. 24, 25 Despite the improvement in defining 'structural matching', mHA differences can not be detected by current molecular techniques. A complementary approach to histocompatibility matching is to measure donor/recipient alloreactivity using functional in vitro assays, ie CTL-p, IL-2/HTL-p and IL-4/HTL-p 26 frequency evaluations. In recent years these assays have been carried out either separately or, more recently, combined [27] [28] [29] and have been applied both in matched unrelated and related BMT. Nevertheless, the clinical relevance of functional assays is still controversial. High frequencies of HTL-p have been shown to correlate with an increased risk for aGVHD development in unrelated donor 13 and HLA-identical sibling 5, 6, 23, 30 BMT, although this can not always be confirmed. 15, 31 Several studies 7, 32, 33 have demonstrated a correlation between high CTL-p frequencies and a significantly higher incidence of severe aGVHD and death in unrelated donor BMT, whereas in other reports 34, 35 these results have not as yet been confirmed. In HLA-identical sibling BMT, the CTL-p assay did not appear to be sensitive enough to provide similar predictive information. 7, [14] [15] [16] [17] In several studies, 7, 16, 17 the lack of sensitivity was already reflected in the low frequencies observed before BMT, generally varying between 1:1 ϫ 10 5 and undetectable levels. Positive frequencies, however, have been detected before and after BMT, but did not always correlate with GVHD occurrence. 14, 15, 36, 37 In our experience, undetectable CTL-p responses were found in all seven monozygotic twin pairs analyzed in a previous study where a comparison of CTLp frequencies in five groups with an increasing degree of HLA mismatch was performed (P Affaticati, manuscript in preparation).
In the present work, positive CTL-p frequencies were found in 21 out of 51 (41.2%) HLA-identical sibling pairs. Statistical analysis revealed a correlation between the frequency of donor host-specific CTL-p and the development of clinically significant aGVHD after transplantation. Moreover, a positive trend for an HF CTL-p response according to an increasing grade of aGVHD was found. The higher sensitivity observed here could be related to the larger number of patients studied. In fact, in the aforementioned studies, relatively few (10-20) patients were analyzed. Our present results are encouraging, but should be confirmed in a larger cohort of patients.
The threshold value of 1:100 ϫ 10 3 , defined by previous studies, [5] [6] [7] 15, 23 has been confirmed by our own data. Recently, Lachance et al 30 ) responses. If our data were re-analyzed using this cut-off point dividing patients into HF and LF groups, the OR was lower (data not shown). The threshold value of 1:100 ϫ 10 3 , with higher OR, was the best cutoff value for the prediction of clinically significant aGVHD.
However, even though a relationship has been shown, some factors can limit the achievement of a very strong correlation. Firstly, there is the restricted tissue distribution of some mHA antigens. 5, 13, 38 Antigens capable of initiating aGVHD may not be expressed by the PBMC used as stimulator cells in the assay, thus avoiding detection in the CTLp assay. This could explain why, in our study, 12 out of 30 patients with a low CTL-p frequency developed severe
Bone Marrow Transplantation aGVHD. The use of tissue-specific cells, i.e. epidermal cells, as stimulators was proposed in order to overcome this problem. 16, 39 Otherwise, antigens present only on the stimulator PBMC may result in high frequency, indicating a GVL reaction rather than a GVH reaction, 40 possibly explaining why, in our series, six out of 21 patients with a high CTL-p frequency did not develop clinically significant aGVHD.
Secondly, the CTL-p assay may detect mHA differences whenever these antigens are expressed on HLA class I molecules, although a low frequency of cytotoxic CD4 ϩ T lymphocytes, sensitive to HLA class II differences, has been detected. 13 In further analyses, the CTL-p frequencies were compared with other functional parameters, such as patient and donor age, time to engraftment, source of stem cells, sex mismatch (female donor/male recipient), aGVHD onset and relapse. No significant relationship among CTL-p frequencies and these parameters was found, except that a shorter platelet engraftment time was observed in patients with high CTL-p frequency. A similar result was obtained by Spencer et al 32 regarding neutrophil engraftment time. The explanation for these phenomena is at present conjectural.
In previous studies, 41 it has been suggested that GVHD is more frequent in male recipients of a marrow from female donors, as a result of a mismatch for the male-specific mHA H-Y between donor and recipient. Considering the absence of correlation between CTL-p frequency and sex mismatch in our data, the absence of an H-Y effect on the alloreactivity development, which is the cause of aGVHD, seems surprising. However, in more recent analyses, no H-Y effect has been observed; 36, 42 this is in agreement with our results.
One may argue that the donor population could be sensitized to mHA in vivo by pregnancy or blood transfusion. Indeed, in our series, no statistical correlation was demonstrated between CTL-p frequency and number of pregnancies (data not shown). The influence of blood transfusion was not significant due to the small percentage of donors who received blood products prior to harvest.
In a recent work on HLA-identical sibling BMT, 30 a predictive value of donor HTL-p frequency for aGVHD and relapse was demonstrated. HTL-p frequencies were significantly higher in patients with severe aGVHD. Patients relapsing had significantly lower HTL-p frequencies. These findings, together with several other observations [43] [44] [45] support the existence of an anti-tumoral effect mediated through the GVH reactions. A relationship between CTLp and relapse was not found in this study. It is possible to argue that the postulated anti-leukemic activity associated with high frequencies of CTL-p might be inhibited by the immunosuppressive therapy administered to patients included in our series who developed severe aGVHD, thereby down-regulating the GVL effect. Nevertheless, mounting evidence obtained both in murine 46, 47 and human [48] [49] [50] models indicates that the GVL effect may, at least partially, be separated from the GVH reaction. Montagna et al 51 demonstrated that donor-derived CTL-p with anti-leukemia activity, persisting for several months after transplantation and protecting from relapse, were not related to the development and severity of GVHD. These observations and our current results seem to suggest that the T cell populations mediating GVL and GVHD could be, at least partially, distinguished, probably because they are specifically directed towards different targets of alloantigens. Some mHA have, in fact, a restricted tissue distribution. HA-1 and HA-2 are expressed exclusively on hematopoietic cells, including leukemic cells, and not on those derived from GVHD target organs. 38, 52 Consequently, HA-1 and HA-2 are the candidates for adoptive immunotherapy of leukemia. HA-1-and and HA-2-specific CTLs, ex vivo generated, can be used to specifically eliminate the relapsed leukemia with a low risk of GVHD. 40 In conclusion, we found a significant relationship between CTL-p frequency and aGVHD severity in HLAidentical sibling BMT. Based on our data, we feel that the CTL-p assay could be a useful in vitro tool for detecting the clinically important alloreactivity that in genotypically HLA-identical siblings is most likely caused by mHA differences.
Hence, the CTL-p assay may also provide useful information in HLA-identical sibling BMT, both in selecting the best donor/recipient combination, (if more than one donor is HLA-matched with the patient), and, most importantly, in suggesting the need to intensify the GVHD prophylaxis when the only available donor has a high CTL-p frequency.
